Home / Intelligence / Blog / Key Changes to Health Technology Assessments (HTAs) in the UK
Published February 2, 2022

The National Institute for Health and Care Excellence (NICE) will mark the start of 2022 by implementing changes to health technology assessments (HTAs), demonstrating adaptability of regulatory bodies as medical technologies continue to evolve. The final HTA changes aim to provide earlier and more equitable access to treatments as well as display increased flexibility in the evaluation of new health technologies. As part of NICE’s plan to modernize healthcare, the changes will apply to both digital therapeutics as well as pharmaceutical products.

New NICE Evaluation Guidelines Will Take Effect in February 2022
NICE will adopt a ‘rolling’ review and evolution of all evaluation guidelines, prioritizing real world evidence (RWE), and customizing evaluations to best assess novel innovations (e.g., acknowledging unique requirements of personalized medicine vs. digital therapeutics) in an agile manner. The impact of the changes will likely not be seen until later in the year as the new evaluation process comes into effect starting next month, but competition can be expected between the UK and the EU for the initial launch of new innovative treatments. A faster assessment adds appeal for companies, especially those that may need to prioritize resources across markets.
The Evolution of NICE Guidelines With Novel Innovations, Including Digital Therapeutics
The new tailored approach for assessment also paves the way for increasing the availability of innovative treatments, including digital therapeutic products; Professor Gillian Leng, NICE chief executive, said that “our vision at NICE is to be at the forefront of delivering access for patients in the NHS to valuable, evidence-based innovative medicines, medical devices and diagnostics,” with the goal of the new updates to enable NICE to “remain cutting edge as the healthcare landscape continues to evolve.”
By Crystal Zhao and Kate Watkins
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
Available On Demand
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Watch Now